NCT07203144RecruitingPhase 2
Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (estimated)
- First submitted
- 24 Sept 2025
- Start date
- 31 Dec 2025
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- First Affiliated Hospital of Chongqing Medical University
- Diseases
- Depression
- NCT number
- NCT07203144
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 172
- From 31 Dec 2025 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently taking medications contraindicated with the investigational drug or that may interfere with its efficacy;
- Those who have received modified electroconvulsive therapy (MECT) within the past 12 months;
Other illness
- Patients with severe psychiatric disorders such as bipolar disorder, schizophrenia, bulimia nervosa, anorexia nervosa, or primary obsessive-compulsive disorder;
- Those with severe physical illnesses or other life-threatening conditions; patients in a current depressive episode with a clear suicidal plan or history of suicide attempt;
- Individuals with a history of substance or drug abuse;
- Those requiring immediate hospitalization for psychiatric disorders;
- Individuals allergic to selenium yeast protein, including those with allergic rhinitis, gastrointestinal sensitivity, allergic constitution, or autoimmune diseases such as Graves' disease or Hashimoto's thyroiditis;
Other
- Patients with contraindications to magnetic resonance imaging (MRI);
- Left-handed individuals.
Who the study is looking for
- Aged 12-18 years;
- Diagnosed with major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), using the K-SADS-PL diagnostic tool;
- A score of ≥40 on the Children's Depression Rating Scale-Revised (CDRS-R);
- Adequate visual and auditory abilities to complete the study;
- Willingness to participate in the study with informed consent signed by both the participant and a legal guardian.
Age in the registry: 12 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Chongqing Medical University Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.